This review assesses current evidence on the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes in patients with RAS wild-type metastatic colorectal cancer. The gene discussed is ERBB2; the disease is metastatic colorectal cancer.